Efficacy of a Gamified Augmented Reality Exposure-based Application in Subjects With Fear of Spiders
Launched by PROF. DOMINIQUE DE QUERVAIN, MD · Nov 11, 2019
Trial Information
Current as of June 01, 2025
Completed
Keywords
ClinConnect Summary
The study will be conducted as a randomized controlled between subject trial. The study consists of two visits and a home training for one group. 60 participants between 18 and 40 years with clinical or subclinical fear of spiders will take part in the study.
All assessments of outcome will be conducted on one visit for each participant, including an in vivo BAT. The experimental group will participate in a home training with the app, spanning over two weeks (6x30-minutes sessions), whereas the control group will not receive any treatment (untreated comparison group).
Six weeks after the ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Fear of spiders
- • BAT score before exposure between 1-8
- • Physically healthy
- • Fluent in German
- Exclusion Criteria:
- • BDI-II sumscore \>=20 and/or item 9 \>=1
- • Concurrent psychotherapy or pharmacotherapy
- • Previous exposure-based therapy for spider phobia
- • Parallel participation in another study
- • Chronic medication intake (except oral contraceptives)
- • Medication intake before visits (less than 24h)
- • Alcohol intake before visits (less than 12 h)
- • Cannabis or other psychoactive substances (including benzodiazepines) intake before visits (less than 5 days)
- • For women: Current pregnancy
About Prof. Dominique De Quervain, Md
Professor Dominique de Quervain, MD, is a distinguished clinical researcher and expert in the field of neuroscience, with a focus on understanding the neurobiological underpinnings of memory and emotional processing. His work encompasses a range of innovative clinical trials aimed at exploring novel therapeutic approaches for cognitive and mood disorders. With a commitment to advancing medical knowledge and patient care, Professor de Quervain's research integrates cutting-edge methodologies and interdisciplinary collaboration, positioning him as a leader in the pursuit of effective treatments for complex neuropsychiatric conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Bs, Switzerland
Patients applied
Trial Officials
Dominique de Quervain, Prof.
Principal Investigator
University of Basel
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials